The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...
Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Please find enclosed communication for the attention of the shareholders of the Company for Apportionment of Cost of Acquisition of Equity Shares of Sanofi India Limited and Sanofi Consumer Healthcare ...
Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,385.85 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...